Key Points {#FPar1}
==========

Osteoporosis (OP) is a common comorbidity in rheumatoid arthritis (RA) and should be considered an extra-articular manifestation.Treatment of OP in RA needs a holistic approach, taking into account both osteoporotic-related risk factors and rheumatoid-related factors.

Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by symmetrical inflammation of the synovium, particularly in the smaller parts of the hands and feet. The prevalence of RA has been estimated to be approximately 1.0% in the general population and affects women more often than men. Due to the inflammatory burden of the disease, RA patients experience tenderness and articular damage of various joints, leading to functional disability, reduced quality of life, and reduced life expectancy \[[@CR1]--[@CR4]\]. The manifestations of RA are not limited to joint inflammation, as extra-articular manifestations (EAM) such as, for example, rheumatoid nodules, vasculitis, (epi)scleritis, pulmonary fibrosis, pericarditis, or Felty syndrome, are present in approximately 40% of RA patients \[[@CR5]\].

A characteristic feature of (preclinical) RA is local bone loss, also called periarticular osteopenia, due to a decrease in bone trabeculae and the presence of bone marrow edema \[[@CR6]--[@CR8]\]. Periarticular bone loss is a consequence of the ongoing impact of inflammatory cytokines such as interleukin (IL)-6 or tumor necrosis factor (TNF) on the (peri)articular sites, and is more frequently present in RA patients with autoantibodies against citrullinated proteins (ACPAs) \[[@CR7], [@CR9], [@CR10]\]. It has been demonstrated that ACPAs are already present years before the clinical onset of RA, therefore it is not surprising that, in some patients, local bone loss is already present in the preclinical phase of RA \[[@CR11], [@CR12]\]. Interestingly, recent studies suggest a direct association between low bone mass (i.e. bone mineral density \[BMD\]) and bone morphometric parameters (i.e. bone quality) and anti-CCP antibody (ACPA) titers in RA patients \[[@CR13], [@CR14]\]. Local bone loss at periarticular sites is a result of cortical bone thinning at the insertion sites of the inflamed synovium, which is the predominant localization of bone erosion development \[[@CR8], [@CR15]\]. Next to localized bone loss, generalized osteoporosis (OP) is a common EAM, especially in patients with longstanding and uncontrolled RA \[[@CR16]--[@CR18]\]. Since these patients have a higher risk for fragility fractures (i.e. hip and vertebral fractures) \[[@CR19], [@CR20]\], and these fragility fractures are related to a higher disease burden, impaired quality of life, increased health care costs, and an augmented mortality rate \[[@CR21]\], more awareness for OP and the treatment of this comorbid condition in RA patients is needed. Therefore, this review aims to provide a practical guide for clinicians for pharmacological treatment options in RA patients suffering from OP.

Epidemiology {#Sec2}
============

In RA patients, decreased mean BMD values of the spine and hips, compared with healthy individuals, has been known to be a very common EAM of RA for several years. In earlier studies, before the introduction of biologics, the prevalence of loss of BMD has been estimated to be doubled in both male and female RA patients compared with healthy controls at both the lumbar spine and the hip \[[@CR16], [@CR17]\]. In these studies, up to 32% of subjects experience loss of BMD, compared with only 16% in the 'healthy' reference group. Moreover, it was observed that RA patients have double the risk of both hip fractures and vertebral fractures, with prevalence estimates ranging from 13 to 36% depending on clinical parameters such as disease burden and duration, concomitant medication, history of (non)vertebral fractures, and age \[[@CR19], [@CR22]--[@CR24]\].

In the Oslo RA register, postmenopausal female RA and non-RA patients were included, with a mean age of ≥ 63 years in both groups. In this study, substantially more vertebral deformities were observed in RA patients compared with non-RA patients, i.e. 147 and 51 vertebral deformities, respectively. Fifty-five (22.1%) patients with RA, compared with 38 (15.3%) controls, had at least one vertebral deformity measured morphometrically \[odds ratio (OR) 1.74, 95% confidence interval (CI) 1.02--3.04\], and 28 (11.2%) versus 12 (4.8%) had two or more deformities (OR 2.60, 95% CI 1.21--6.04) \[[@CR22]\].

In the British General Practice Research Database (BGPRD), fracture rates were compared between RA and non-RA patients in different age groups. This registry observed that RA patients had comparable increases in fracture risk, with an adjusted relative risk (RR) for clinical osteoporotic fracture of 1.4 (95% CI 1.2--1.7) in male RA patients and 1.5 (95% CI 1.4--1.6) in female RA patients, in all age groups, when compared with non-RA patients. Interestingly, it was shown that there were an increasing number of fracture rates in patients of higher age groups, especially in patients aged 70 years and older \[[@CR19]\].

The burden of OP (i.e. OP-related fractures) in RA patients can be explained by several reasons (Fig. [1](#Fig1){ref-type="fig"}). First, RA is a chronic disabling inflammatory disease that is associated with decreased mobility and physical activity, as well as lower muscle mass and sarcopenia, all factors known to have detrimental effects on bone mass \[[@CR25]--[@CR28]\]. Second, for several years now, the direct effects of inflammation on bone density have been known, especially in newly diagnosed RA patients \[[@CR29]\]. Moreover, it has been observed that inflammation and bone loss share common pathways in pathogenesis \[[@CR30]--[@CR32]\].Fig. 1Risk factors for osteoporosis in rheumatoid arthritis

Intriguingly, van Staa et al. observed that RA patients without prior GC use had an increased risk for both vertebral fractures (RR 1.5, 95% CI 1.2--1.9) and hip fractures (RR 1.7, 95% CI 1.5--2.0) compared with controls without a history of RA, at any time during follow-up. In addition, increased risk was also seen in early glucocorticoid (GC) users, not just in chronic users, suggesting that the underlying active disease with ongoing inflammation and muscle weakness should be considered a relevant risk factor for increased prevalence of OP and the incidence of fractures \[[@CR19]\]. Third, it is known that GCs have direct and indirect negative effects on bone density \[[@CR33], [@CR34]\]. Indeed, previous studies have estimated that 30% of all patients treated with GCs for at least 6 months will develop OP \[[@CR35]\]. Therefore, RA patients with (long-term) GC exposure have an accelerated risk for glucocorticoid-induced OP (GIOP) during their lifetime. For the abovementioned reasons, in relation to RA and the presence of classical risk factors for OP (e.g. familial OP or hip fracture and postmenopausal age), many RA patients suffer from both OP and an augmented fracture rate.

Fracture Risk Assessment {#Sec3}
========================

OP is defined as a musculoskeletal disorder characterized by compromised bone strength, predisposing individuals to an increased fracture risk \[[@CR36]\]. Individuals can be divided into three groups according to the WHO criteria, dependent on the BMD value: *T* score ≧ − 1 = normal BMD; − 2.5 \< *T* score \< − 1 = osteopenia and *T* score ≦ − 2.5 = OP. However, most fractures occur paradoxically in patients not suffering from OP but suffering from osteopenia, and this can be partly explained by the fact that these patients also have impaired quality of bone, which is not measured with DXA \[[@CR37], [@CR38]\]. Moreover, in all patients, vertebral fracture assessment (VFA) is recommended. The gold standard for detecting vertebral fractures is a conventional radiograph of the thoracolumbar spine. In clinical practice, the Genant score is used, in which the degree of height loss is assessed and can be graded as mild (grade 1, 20--25% height loss), moderate (grade 2, 25--40% height loss), or severe (grade 3, \> 40% height loss) \[[@CR39]\]. However, VFA is an elegant alternative because this technique has been proven to be safe, with less radiation exposure, is less time-consuming, and has lower costs than conventional radiographs with comparable accuracy in detecting moderate-to-severe vertebral fractures \[[@CR40]\]. Another way to assess fracture risk is to calculate the 10-year probability for a major fracture (i.e. vertebral, hip, humerus, or wrist fracture) using the computer-based algorithm FRAX^®^ \[[@CR41]\]. This algorithm includes several clinical risk factors, including, among others, previous fractures, parental history of hip fracture, age, smoking, GC use, and secondary causes for OP, including RA. Although FRAX^®^ is very useful in daily clinical practice, this calculation tool has some disadvantages for RA patients as it does not take into account the cumulative disease burden and disease activity, which are notorious independent risk factors for bone loss in RA. Therefore, it has been suggested that FRAX^®^ might underestimate the fracture risk in these patients \[[@CR42], [@CR43]\]. Other limitations of this fracture risk calculation tool include the fact that it does not take into account fall risk, vertebral fractures, and the dose of GC in the FRAX algorithm. Moreover, it was observed that the risk of a subsequent fracture after an initial fracture, is strongly upregulated in the first 2 years \[[@CR44]\]. Although the FRAX^®^ has some limitations, in daily clinical practice FRAX® is an adequate algorithm to identify high-risk RA patients and to determine which RA patients should be treated according to (inter)national guidelines \[[@CR45]\].

Nonpharmacological Interventions {#Sec4}
================================

Although no randomized controlled studies have been performed on nonpharmacological interventions and fracture reduction, some general measures have been advocated in OP patients. First, a healthy lifestyle, including nonsmoking, little to no alcohol intake, and a nonsedentary and active lifestyle with exercises, should be advised in all patients in order to reduce bone loss \[[@CR46]--[@CR48]\]. Moreover, adequate calcium intake up to a daily dose of 1000--1200 mg is necessary; if daily intake is below this threshold, calcium supplementation is needed. Although calcium supplementation is needed in patients with a low calcium intake, high dietary calcium intake has been debated as supplementation has been associated with an elevated risk of cardiovascular disease (CVD) \[[@CR49]\]. This is a concern, particularly in RA patients, as RA has been associated with an increased risk of CVD that equals the CVD risk of diabetes mellitus \[[@CR50]\]. Moreover, a recent study showed an increased risk of CVD in RA patients with fragility fractures \[[@CR51]\]. Another nonpharmacological modifiable factor is vitamin D deficiency, as a large meta-analysis has shown that vitamin D supplementation (800 IU/day) in patients who also received calcium supplementation is associated with a 20% reduction in falls and nonvertebral fractures \[[@CR52], [@CR53]\]. Therefore, supplementation of calcium and vitamin D is needed, along with general advice regarding low alcohol intake, cessation of smoking, and performing exercises to reduce fracture risk in RA patients.

Anti-osteoporotic Drugs in Rheumatoid Arthritis {#Sec5}
===============================================

Bisphosphonates {#Sec6}
---------------

To date, no randomized controlled trials with bisphosphonates (BPs) have been conducted in osteoporotic RA patients with fractures as the primary outcome measure. Nevertheless, osteoporotic RA patients have been included in GIOP trials; therefore, from these RCTs, sparse data and indirect evidence on fracture reduction in osteoporotic RA patients treated with BPs are available \[[@CR54]\]. Looking into these GIOP studies in more detail, a strong reduction in vertebral fractures was shown in BP-treated GIOP patients (RR 0.57, 95% CI 0.35--0.91) and a nonsignificant reduction in non-vertebral fractures has been observed (RR 0.79, 95% CI 0.47--1.33); however, most of the randomized controlled trials did not specify whether these were RA patients. Moreover, due to limited number of RA patients or the limited number of incident fractures due to the short follow-up duration, outcome data on fractures could not be specified.

The study performed by Lems et al. focused specifically on the effects of BPs in RA patients treated with low-dose prednisolone \[[@CR55]\]. In that double-blind, placebo-controlled RCT, 163 RA patients who were treated with low-dose prednisone (≤ 10 mg/day) for at least 3 months were enrolled. Patients were randomized to receive daily doses of alendronate or placebo. Compared with placebo, a significant increase in BMD as the primary outcome at both the lumbar spine and the hip was shown after 1 year in the BP-treated group. As a secondary outcome, the fracture incidence was evaluated in both the BP- and placebo-treated groups. Overall, no significant differences were observed between fractures. Remarkably, there was a trend towards a higher incidence of vertebral deformities in the alendronate-treated patients, which seems to be in conflict with the favorable effects of alendronate on both BMD and markers of bone turnover. However, a probable explanation is that the alendronate-treated patients had more severe OP, as these patients had more prevalent vertebral fractures at baseline compared with patients in the placebo group.

Hence, to summarize the evidence of fracture risk reduction of BPs in RA patients, in general, BPs have been shown to reduce the risk of vertebral fractures in GIOP patients (including RA patients), but only one study focused on BPs and fracture risk in RA patients, showing significant BMD improvement, but no difference in fracture risk reduction compared with placebo, possibly due to the short follow-up duration.

Modern Treatment Options in Osteoporosis (OP): Teriparatide and Denosumab {#Sec7}
-------------------------------------------------------------------------

### Teriparatide {#Sec8}

Teriparatide is a parathyroid hormone analog that is administered subcutaneously daily. It acts as an anabolic drug by increasing bone formation by decreasing osteoblast and osteocyte apoptosis and stimulating osteoblasts. Several studies showed fracture risk reduction in (postmenopausal) women and men \[[@CR56]\].

In GIOP patients, including patients with rheumatic disorders such as RA, a landmark study showed that teriparatide, compared with the active comparator and antiresorptive drug alendronate, resulted in not only significantly more increases in BMD levels but also in significant vertebral fracture reduction, which was confirmed in the extension study and in daily clinical practice \[[@CR57]--[@CR59]\]. The efficacy of teriparatide has been studied in osteoporotic RA patients (*n* = 70) compared with postmenopausal osteoporotic patients without RA (*n* = 62) \[[@CR60]\]. Interestingly, this study observed greater responses to teriparatide on bone formation markers bone alkaline phosphatase and P1NP at 1 month of treatment, and on femoral neck BMD after 18 months of treatment (4.7 vs. 0.7%, *p* = 0.038), but not on the lumbar spine and BMD levels in RA patients compared with osteoporotic patients. However, no differences in fracture rate could be detected in this small case-control study.

Another nonrandomized observational study by the same research group assessed the effects on BMD outcome after either continuing BP, switching from a BP to teriparatide, or switching from BP to denosumab in a group of 194 RA patients with, on average, over 3 years of BP use \[[@CR61]\]. During the 18-month follow-up period, the group continuing BPs experienced an 8.8% incident fracture, compared with only 4.1% and 2.5% in denosumab-treated and teriparatide-treated patients, respectively.

In a recently published study by Langdahl et al., an integrated analysis of four prospective observational studies including approximately 8900 patients, and with approximately 900 RA patients included, found RA to be an important risk factor for fractures \[[@CR62]\]. In that study, it was observed that RA patients treated with teriparatide showed significant reductions in vertebral and nonvertebral fractures. Therefore, it can be concluded that teriparatide is a pivotal bone formation drug that showed fracture reduction not only in OP patients but also in RA patients. Abaloparatide and romosozumab are new anabolic agents that have been approved in US for postmenopausal women, but not (yet) in Europe. Both abaloparatide and romosozumab have not been tested in GC users.

### Denosumab {#Sec9}

Denosumab is a fully human monoclonal antibody to an activator of osteoclastic differentiation and proliferation, soluble RANK-L. RANK-L is upregulated in postmenopausal women and in patients in an inflammatory state, such as RA \[[@CR63], [@CR64]\]. In postmenopausal women, denosumab has shown strong bone protective properties, as reported in the FREEDOM phase III trial. An RR reduction of vertebral, nonvertebral, and hip fractures compared with placebo was found in 68%, 20%, and 40% of patients, respectively \[[@CR65]\]. In RA patients, there are some data on denosumab and OP.

Recently, it was found that compared with risedronate, denosumab had superior effects on spine and hip BMD after 1 year, which continued after 2 years in patients with GIOP \[[@CR66], [@CR67]\]. In this large, randomized controlled trial in more than 700 patients, approximately 40% of patients had RA. Despite the superior effects on BMD, no differences were observed in vertebral, hip, and nonvertebral fractures. At first sight, this could be disappointing, but the study was smaller (295 denosumab-treated patients vs. 295 alendronate-treated patients), the observation time was shorter (1 vs. 3 years), and denosumab was tested against placebo in the phase III FREEDOM study, and also against the active comparator risedronate in the GIOP study.

In a phase II, randomized controlled trial in 350 RA patients taking methotrexate, denosumab every 6, 3, or 2 months, or placebo, was added to methotrexate treatment to study the effects of denosumab on radiographic progression in RA patients. Not surprisingly, BMD significantly increased at both lumbar spine and total hip level in the denosumab groups compared with placebo at 6 and 12 months \[[@CR68]\]. Intriguingly, this study also showed that denosumab significantly inhibits radiographic progression at the joints, as the modified Sharp erosion score showed less increase in the denosumab-treated groups compared with the placebo groups (0.27, 0.14, and 0.09 for denosumab every 6, 3, or 2 months, respectively, versus 0.99 in the placebo group), while no difference was found in joint space narrowing. Moreover, a higher percentage of RA patients taking methotrexate had no deterioration in disease progression in the modified Sharp erosion score in the denosumab group (78.8, 80.5, and 83.5 in the denosumab groups, versus 62.5% in the placebo group). In the recently published DESIRABLE study, which included 650 RA patients taking conventional disease-modifying antirheumatic drugs (cDMARDs), these observations were replicated in a well-conducted, randomized, placebo-controlled trial, as this study clearly showed that compared with placebo, denosumab significantly inhibited the progression of joint destruction and increased lumbar spine BMD in patients receiving concomitant csDMARD treatment \[[@CR69]\]. However, no changes in the disease activity of RA were observed in the denosumab-treated groups compared with the placebo group, indicating that denosumab acts directly on the bone metabolism and has no clinically relevant effects on cartilage and the immune system. Importantly, no differences in adverse events were observed between the denosumab-treated groups and placebo, which is in line with previous observations in RA patients that denosumab use, compared with non-denosumab use, was not associated with an elevated infection risk, even in patients with concomitant biological DMARD (bDMARD) use \[[@CR67]\]. Moreover, it was observed that concomitant denosumab use with bDMARDs had a protective effect on bone erosion development compared with RA patients treated with bDMARDs only \[[@CR70], [@CR71]\]. These studies emphasize the disease-modifying role of denosumab in RA patients in reducing radiologic joint damage progression, which was previously stated in the 2017 systematic review by Boleto and colleagues \[[@CR72]\].

In another study, it was shown that the combination of calcium and vitamin D supplementation with denosumab enhances BMD more than denosumab monotherapy in RA patients with OP. However, no fractures were observed in both denosumab groups, suggesting a bone protective role in denosumab-treated RA patients \[[@CR73]\]. This is in line with the observed fracture risk reduction when patients switched from BPs to a bone protective agent with another mode of action, such as denosumab (4.1% vs. 8.8%) \[[@CR61]\]. Therefore, it can be concluded that denosumab significantly increases BMD levels and seems to decrease fracture risk in RA patients, especially when denosumab is combined with calcium D supplementation. Moreover, bone erosion development seems to be arrested in denosumab-treated RA patients, with concomitant methotrexate or bDMARD use.

Disease-Modifying Antirheumatic Drugs (DMARDs) {#Sec10}
==============================================

Conventional DMARDs {#Sec11}
-------------------

Methotrexate and other cDMARDs, such as leflunomide, hydroxychloroquine, and sulfasalazine, are standard drugs in the RA treatment arsenal of rheumatologists. These drugs reduce the disease activity in RA, which may slow down joint damage progression. Since BMD loss in RA is related to disease activity, the use of DMARDs may improve BMD levels. Previously, it was shown that RA patients in clinical remission more often have gain in bone density, while patients with persisting disease activity have rarely any gain in bone density \[[@CR74]\]. However, only little evidence is available on cDMARDs and OP and fracture risk in RA.

Looking at the link between the anchor drug for RA, methotrexate, and OP, only a few studies exist. In an observational study of approximately 100 RA patients, no deterioration in BMD was observed in the methotrexate-treated patients (*n* = 68) compared with the patients treated with other cDMARDs \[[@CR75]\]. However, the combination of corticosteroids and methotrexate showed larger decreases in BMD compared with corticosteroids in patients not treated with methotrexate. Other studies on BMD levels and methotrexate in RA patients have been performed, but in these studies no impairment of BMD in approximately 450 methotrexate-treated RA patients compared with other DMARD treatment was observed \[[@CR76]--[@CR80]\]. Surprisingly, some negative effects have been postulated for the anchor drug methotrexate, as methotrexate might jeopardize bone density by direct negative effects on the osteoblast activity \[[@CR81]\]. This can potentially lead to spontaneous stress fractures, a condition that has been called 'methotrexate osteopathy'. Methotrexate osteopathy has been predominately described in patients with hematologic conditions, with much higher doses used than in rheumatology conditions such as RA \[[@CR82]\].

Data on the relation between cDMARDs, other than methotrexate, and BMD levels, OP, and fracture risk are scarce. To the best of our knowledge, only one study has been conducted on other cDMARDs and BMD levels. In that study, 153 RA patients with newly diagnosed OP were followed for 1 year, and BMD levels were assessed in these patients \[[@CR83]\]. The study showed that the only cDMARD (including methotrexate, sulfasalazine, leflunomide and hydroxychloroquine) associated with BMD improvement at the lumbar spine in multivariate analysis was leflunomide. However, these results should be interpreted with caution as the study was not a randomized, placebo-controlled trial. Therefore, in general, no impairment in BMD has been observed for cDMARDs, although the most critical conclusion is that the data are based on a limited number of patients with a variety of disease activities and other confounders.

Biological and Targeted Synthetic DMARDs {#Sec12}
----------------------------------------

### Tumor Necrosis Factor Inhibitors {#Sec13}

Tumor necrosis factor (TNF) inhibitors were the first biologics used in RA treatment, and are pivotal agents in the inhibition of inflammation. Inflammatory cytokines such as TNF induce osteoclast maturation and suppress osteoblast activation by the Dickkopf-1 and disturb bone homeostasis in this manner \[[@CR84], [@CR85]\]. Therefore, anti-TNF treatment may improve bone homeostasis in RA patients. Indeed, several studies showed positive effects on bone density and bone turnover in RA patients. Vis et al. were one of the first to report the beneficial effects on bone metabolism in RA patients treated with infliximab \[[@CR86]\]. Most studies on the effects of TNF blocking and bone loss have been performed with infliximab in RA. These studies observed preservation or improvement of BMD at the lumbar spine and hip, as well as a decrease in bone resorption markers \[e.g. Carboxy terminal crosslinked telopeptides (CTX)\] and an increase in bone formation markers (e.g. P1NP) \[[@CR87]\]. Similar effects on BMD have been described for other TNF inhibitors such as etanercept and adalimumab \[[@CR88], [@CR89]\]. Although favorable effects on BMD levels have been reported, some degree of caution is needed as most of these studies have a short follow-up period and the favorable effects on BMD in relatively small studies are not accompanied by data on fracture risk. Only a few studies investigated whether TNF-blocking agents decrease the fracture incidence rate in RA patients. In a large, population-based study in more than 16,000 RA patients, fracture risk incidence was compared between three different treatment modalities, i.e. RA patients treated with TNF inhibitors, RA patients treated with the cDMARD methotrexate, and RA patients treated with cDMARDs other than MTX \[[@CR90]\]. Remarkably, this study observed no differences in the non-vertebral fracture risk incidence rates. The results might be explained by confounding by indication, since anti-TNF is probably prescribed in the most severe RA patients. As a consequence, an increased fracture risk should be expected. The fact that no increased fracture risk was found could be seen as a favorable result.

In another cohort study with approximately 22,000 RA patients treated with TNF inhibitors, no increased incidence fracture rates were observed \[[@CR91]\]. However, looking carefully at the data, patients treated with anti-TNF had more EAMs and used more corticosteroids, suggesting that RA patients treated with TNF inhibitors suffered a more severe disease, with more risk factors for osteoporotic fractures. Finally, the North American CORRONA registry with approximately 8500 female RA patients, observed a reduced risk for incident fractures in the anti-TNF group compared with the methotrexate-only group \[[@CR92]\]. This is in line with the recent longitudinal prospective observational FORWARD study, a national databank for rheumatic diseases in the US, which observed lower incidence rates for vertebral fractures in RA patients treated with TNF inhibitors \[[@CR93]\]. These studies suggest an osteoprotective role for anti-TNF in RA patients.

### Other Biological and Targeted Synthetic DMARDs {#Sec14}

Data on bDMARDS (such as abatacept, rituximab, tocilizumab, and sarilimumab) and targeted synthetic (ts)DMARDs in relation to BMD and fracture rate in RA are scarce. Treatment with IL-6 inhibition (i.e. sarilumab and tocilizumab) showed some evidence for osteoprotective effects. In tocilizumab-treated RA patients, Garnero et al. described a decline in bone resorption markers, Carboxy terminal crosslinked telopeptides of type I collagen (CTX-1), and increases in the bone formation markers osteocalcin (OC) and N-terminal propeptide of type I collagen (PINP) \[[@CR94]\]. This is in line with the observations made in the MOBILITY trial in sarilumab-treated RA patients. In that study, an improvement in both bone formation and bone resorption markers was shown \[[@CR95]\]. More recently a nationwide study in Israel showed stabilization of BMD levels in RA patients during tocilizumab treatment \[[@CR96]\]. Interestingly, these observations were replicated in a study performed in Taiwan, where Chen et al. showed both improvement of bone turnover markers and BMD at femoral neck and lumbar spine (the latter was not significant) in ACPA-positive RA patients \[[@CR97]\].

Another retrospective observational Japanese study observed larger improvements at hip BMD in RA patients treated with both denosumab and tocilizumab, compared with treatment of RA patients with denosumab and another bDMARD during 18 months of follow-up \[[@CR71]\].

Together, these data at least suggest positive effects of IL-6 inhibition on bone metabolism. For the B lymphocyte-depleting therapy rituximab, data in RA patients is even more limited.

This monoclonal antibody targeting CD20-positive B cells has shown some decline in bone resorption markers during rituximab therapy in RA patients \[[@CR98], [@CR99]\]. More recently, some exciting data have been reported that rituximab may improve BMD, but these results are preliminary due to the low number of patients and the short duration of follow-up in these rituximab-treated RA patients; therefore, the (long-term) effects of B lymphocyte depletion on OP and fractures remains to be established \[[@CR100]--[@CR102]\].

Abatacept is a soluble fusion protein (CTLA4) that blocks CD28 to bind to antigen-presenting cells (APC) with CD80/CD86 on its surface; however, due to this co-stimulation blockade, T lymphocytes are not activated. For several years, abatacept has been known as a good bDMARD in moderate to severe RA. Co-stimulation blockade has been found to have some inhibiting effects on osteoclastogenesis, and, hypothetically, may have some osteoprotective effects \[[@CR103], [@CR104]\]. In a prospective, nonrandomized cohort study of 165 RA patients, the effects of abatacept (*n* = 50) on BMD were compared with other biologics (*n* = 115) \[[@CR105]\]. This study showed a incline in the femoral neck BMD in the group of RA patients treated with abatacept, confirming the hypothesized inhibiting effects on osteoclasts.

The most modern and very promising antirheumatic drugs include the JAK inhibitors. Despite no studies having been published on BMD and JAK inhibition, baricitinib has been shown to suppress osteoclast development by inhibiting expression of RANKL on osteoblasts in vitro, while tofacitinib preserved cortical trabecular hardness in rats \[[@CR106], [@CR107]\]. The coming era will reveal whether these drugs will serve as potent osteoprotective agents.

Treatment of OP in RA: A Practical Guide {#Sec15}
========================================

Despite the effective treatment options available nowadays compared with 2--3 decades ago, RA patients still suffer from an increased risk for fractures \[[@CR108]\]. One of the most threatening reasons for the high incidence of fractures, next to aging, and the low adherence of osteoporotic drugs, is the ongoing use of corticosteroids, resulting in GIOP. Although the observation that GC use in early and active RA may not diminish BMD levels \[[@CR109]\], ongoing GC use, even at low doses, is associated with an elevated fracture risk \[[@CR110]\].

To prevent new fractures in RA patients, the following steps may help to identify high-risk OP patients, and may serve as a practical guide for OP treatment in RA.

In our opinion, three measures should be taken into account in the management of OP, as summarized in Table [1](#Tab1){ref-type="table"}: general measures, RA disease-related factors, and OP-related factors.Table 1A practical guide for fracture risk management in RA patientsGeneral measures Encourage patient to stop smoking and reduce excessive alcohol intake Encourage physical activities and (daily) weight-bearing exercisesRA-related factors Optimal treatment of RA (i.e. treat to target) aiming at remission or low disease activity Prescribe glucocorticoids in the lowest possible dose and for a short periodOP-related factors Assess fracture risk according to (inter)national guidelines, including performance of DXA with VFA Calculate fracture risk in RA patients with osteopenia using calculation tools such as FRAX^®^ Assess dietary calcium intake and supply calcium if needed^a^, as well as vitamin D supplementation Vitamin D supplementation if needed^b^ First-line OP treatment: oral bisphosphonates such as alendronate/risedronate Second-line OP treatment: zoledronic acid/denosumab, teriparatide in patients who fracture during first-line therapy or do not tolerate first-line therapy, and in patients with very high fracture risk, as initial therapy*RA* rheumatoid arthritis, *OP* osteoporosis, *DXA* dual-energy x-ray absorptiometry, *VFA* vertebral fracture assessment^a^Calcium up to a daily intake of 1000--1200 mg is needed^b^25-Hydroxyvitamin D3 serum level \> 50 nmol/L is advised throughout the whole year

First, some general lifestyle advice should be given; a normal body mass index (BMI), smoking cessation, and avoiding excessive alcohol intake should be advocated. Moreover, a non-sedentary and active lifestyle should be advised in all patients in order to reduce bone loss. For this reason, every RA patient should be encouraged to perform physical activities, along with daily, weight-bearing exercises if possible.

Second, some RA-related factors should be taken into account. Most important is to aim at remission or the lowest disease activity as possible, as ongoing inflammation jeopardizes bone quality and should be considered a relevant risk factor for osteoporotic-related fractures \[[@CR19]\]. Although no superiority for a specific treatment regimen has been demonstrated, some (indirect) evidence exists that bDMARDs may be more pivotal for preventing bone loss when looking carefully at fracture data of cDMARDs compared with bDMARDs. The question remains whether this is only explained by the fact that bDMARDs are excellent and better immunosuppressives in reducing inflammation. Unfortunately, bDMARDs are less often prescribed in the elderly; this is critical since the elderly, in particular, are at high fracture risk. Next, in order to aim at the lowest possible disease activity, efforts should be made to prescribe GCs at the lowest possible dose. Again, GCs are often used in the elderly, which may have devastating effects. If possible, doses higher than 7.5 mg should be avoided and prednisolone sparing-agents (e.g. cDMARDs, bDMARDs, or tsDMARDs) should be added if long-term treatment for higher doses is expected. Moreover, GCs should preferably only be used as an induction therapy and for a short period of time when possible.

Third, it is important to manage all OP-related factors. All RA patients with known OP, VF, or RA who are treated with prednisolone for more than 3 months at doses higher than 7.5 mg every day (or GC equivalent), should be treated with anti-osteoporotic medication, along with calcium and vitamin D supplementation. In daily clinical practice, fracture risk should be ascertained using DXA. Along with DXA performance, VFA is recommended in all postmenopausal and male patients aged 50 years and over or RA patients aged 40 years and over who are treated with prednisolone 5 mg (or a GC equivalent) every day for more than 3 months. In case of a VF or *T* score ≤ − 2.5, anti-osteoporotic medication, along with calcium and vitamin D supplementation, should be initiated.

As mentioned above, ongoing inflammation in RA patients due to disease activity threatens bone quality and accelerates bone loss. For this reason, it can be advocated that certain RA patients with high disease burden should be treated with osteoporotic medication to decrease fracture risk. Therefore, in (certain) RA patients, lower treatment thresholds (e.g. a *T* score \< − 2.0) can be recommended to decide whether RA patients should be treated with osteoporotic medication \[[@CR111]\]. Another validated tool to assess (future) fracture risk in RA patients is the FRAX^®^ calculation tool, which should be recommended in all RA patients with a *T* score \> − 2.5, to assess future fracture risk. In RA patients, adequate calcium intake, up to a daily intake of 1000--1200 mg, is needed. Below this threshold, calcium supplementation is needed. Particularly in GC-treated patients, it has been suggested that the daily calcium intake should be above 1000--1200 mg/day \[[@CR112], [@CR113]\]. This recommended dose is slightly higher than the dose recommended for postmenopausal women not using GCs, and is related to the lower intestinal calcium absorption and increased urinary calcium excretion in GC-treated patients. An adequate 25-hydroxyvitamin D3 serum level \> 50 nmol/L is advised throughout the whole year, and also at the end of winter \[[@CR114]\]. If an osteopenic RA patient suffers from a high risk of fracture, or an RA patient has OP, in general the oral BP alendronic acid (or another oral BP such as risedronate) is the first choice as this agent has been shown to improve BMD levels in RA patients. However, sparse data indicate that the modern treatment agents denosumab and teriparatide might be superior, in RA patients, for increases in BMD and fracture rate reduction, compared with the active comparators alendronate or risedronate. Although these pivotal osteoporotic drugs are attractive as first-line therapy, the evidence is too little to include them as first-line drugs for OP in RA. Moreover, these drugs are too costly to be used in all patients. However, in certain patients with a very high fracture risk, i.e. elderly patients with RA, a (very) low BMD, or a recent nonvertebral osteoporotic fracture or known VF, second-line anti-osteoporotic agents are a very attractive option to reduce fracture risk.

We are hopeful that good implementation of the above measures will serve as an ideal form of fracture risk management and will ultimately lead to a reduction in fracture risk in vulnerable RA patients.
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